HealthStream: Q2 Earnings Snapshot

HealthStream Inc. (HSTM) reported Q2 profit of $6.7 million, or 23 cents per share, on revenue of $83.7 million. The company expects full-year revenue of $327 million to $332 million, according to the report.

Original reporting
Published Aug 3, 2026, 10:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 11:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$HSTM
Neutral
medium confidence
Mentioned
$HSTM
Relevance
7/10
AlphAI data visualization · based on greenevillesun.com
Decision brief

The 30-second read

$HSTMNeutralMed
01

Why it matters

The key tradable elements are the reported Q2 profit and revenue, and the stated full-year revenue outlook ($327M to $332M), which can shift analyst models and near-term expectations.

02

Market read

This is a straightforward earnings snapshot with explicit full-year revenue guidance, which can affect estimates and short-term positioning.

03

What to watch

Traders may focus on margins, backlog, and customer retention, none of which are detailed in this snapshot, so the earnings headline may not capture the true driver.

Relevance 7/10Novelty 7/10Timing: reported Monday after-hours/late-day (published 2026-08-03 22:45 UTC)

Background

HealthStream is an internet-based provider of educational and training content for healthcare professionals.

Company-level read

Ticker impact

$HSTMNeutralMedium confidence
Context

HealthStream reported Q2 profit of $6.7M (23 cents/share) and revenue of $83.7M, plus full-year revenue guidance of $327M to $332M.

Expected impact

Likely modest volatility around the earnings release and guidance range, with direction dependent on how the numbers compare to Street expectations.

Evidence & confidence

It includes both reported quarterly results and explicit full-year revenue guidance, but it does not provide consensus comparisons or a surprise magnitude.

Market effects

Adds incremental signal for health-care education and training software/content demand trends, but impact is company-specific.

Limited, as the disclosure is for a single US-listed issuer.

Low, no international or macro linkage beyond healthcare training spend.

Counterpoint

If the guidance range is broadly in line with expectations, the market reaction may fade quickly and the stock may trade more on forward bookings/renewals than on this revenue band.

Key entities

  • HealthStream Inc.

    Reported Q2 profit and revenue and issued full-year revenue guidance.

Related articles

$HSTMMed

WJRJJ Ventures Discloses Investment at HealthStream with 9.6% Stake

WJRJJ Ventures disclosed a 9.6% stake in HealthStream, acquired through open-market buys and a deal at $29.50 per share. The investment includes a one-year standstill and registration rights. WJRJJ plans to hold shares for investment but may buy or sell more over time. Willis Johnson, managing member of WJRJJ, is involved in the investment.

$HSTMHigh

HEALTHSTREAM ANNOUNCES SECOND QUARTER 2026 RESULTS

HEALTHSTREAM INC (HSTM) filed an SEC Form 8-K — Results of Operations and Financial Condition. HealthStream Announces Second Quarter 2026 Results Page 1 August 3, 2026 Exhibit 99.1 Contact: Scott A. Roberts Chief Financial Officer (615) 301-3182 ir@healthstream.com Media: Mollie Condra, Ph.D. Head, Investor Relations & Communications (615) 301-3237 mollie.condra@healthstre

$LEVIHighAI 8/10

Levi's CEO admits the company missed the biggest jeans trend of the year

Levi Strauss & Co. (LEVI) CEO Michelle Gass admitted the company missed the U.S. shift to low-rise jeans during the back-to-school season, impacting its direct-to-consumer sales. Despite a 4% revenue increase to $1.6 billion in Q3, shares fell nearly 5%. Levi's has since refocused marketing on low-rise styles and expects full-year revenue growth of about 6%.

$REGNMed

Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month

Regeneron (REGN) reported positive long-term results for its rare disease drug Pasatru, showing no new abnormal bone growth in an extended Phase 3 trial. The trial enrolled 63 adults, with zero new lesions in the Pasatru group compared to nine in the placebo group. REGN shares rose 2.8%, their best day in over a month. BofA raised its price target to $908, implying 19% upside. The company plans a new study for children and adolescents later this year.